Methods for mitigating bispecific T-cell adapter or chimeric antigen receptor T-cell mediated cytokine release syndrome using interleukin
The treatment of monocytes by using cytokines such as IL-10, IL-4, IL-12, IL-15, IL-7, etc. or their half-life prolonged form of diakine, inhibiting the release of proinflammatory cytokines induced by IL-2, resolved Problems with CRS after BiTE or CAR-T therapy significantly alleviate treatment-related toxicity.
Patent Information
- Application Number
- CN202380023166.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-02-22
- Filing Date
- 2023-02-22
- Publication Date
- 2024-11-05
AI Technical Summary
Cytokine release syndrome (CRS) occurs after receiving BiTE or CAR-T therapy, resulting in uncontrolled secretion of interleukin 6, interleukin 1β, tumor necrosis factor alpha and interferon gamma, triggering a toxic reaction , the prior art has not yet clarified its induction molecular pathway.
Monocytes were treated with IL-10, IL-4, IL-12, IL-15, IL-7 or their half-life prolonged forms, or diakine containing these cytokines to directly inhibit IL-2's proinflammatory cytokines Induce and reduce CRS.
By inhibiting the induction of proinflammatory cytokines by IL-2, it significantly alleviates or prevents BiTE or CAR-T therapy-related CRS and reduces the treatment-related toxicity response.
Smart Images

Figure BDA0005005447520000091 
Figure BDA0005005447520000101 
Figure BDA0005005447520000111
Abstract
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Application No. 63 / 312,697, filed on February 22, 2022, the disclosure of which is incorporated herein by reference in its entirety. References to Electronic Sequence Listings
[0002] The contents of the electronic Sequence Listing (039451-00100-Sequence-Listing.xml; Size: 37,997 bytes; Creation Date: February 22, 2023) are incorporated herein by reference in their entirety. background
[0003] Cytokine release syndrome (CRS) is a dose- and treatment-related toxicity caused by T cell activation with bispecific T cell engagers (BiTE) (Hosseini, 2020) and chimeric antigen receptor T cells (CAR-T) applied to patients (Maude, 2014; Norelli, 2018). CRS is defined as the uncontrolled induction of high levels of interleukin 6 (IL-6) and interleukin 1β (IL-1b) (Liu, 2018) (mainly), tumor necrosis factor alpha (TNFα) (Chen, 2021) and interferon gamma (IFNγ) (Shimabukuro-Vornhagen, 2018) in the serum of treated patients.
[0004] So far, the molecular pathway responsible for inducing CRS is unclear. According to the findings of the present inventors, it has been determined that the induction in BiTE and CAR-T CRS patients may be due to T cell receptor (TCR): BiTE or CAR-T: tumor-associated antigen (TAA) aggregation-mediated CD4+T cell activation. This activation in turn leads to the secretion of IL-2 (Brandl, 2007). The secretion of IL-2 then drives monocytes to secrete proinflammatory cytokines associated with CRS (Bosco, 2000; Musso, 1992; Strieter, 1989). Overview of various implementations
[0005] The present inventors have discovered that treatment of monocytes with IL-10 or IL-4, IL-12, IL-15, IL-7, or any combination of the above substances, or any half-life extended form of the above substances, or with any diakine containing IL-10, IL-4, IL-12, IL-15, IL-7 or IL-2 can engage with the cognate cytokine receptors on monocytes and directly inhibit the induction of proinflammatory cytokines by IL-2.
[0006] In one aspect, the present application relates to a method for treating monocytes with IL-10 or IL-4, IL-12, IL-15, IL-7, a half-life extended form thereof, IL-10 and IL-4, IL-10 and IL-2, IL-10 and IL-7, IL-10 and IL-12, a combination of IL-10 and IL-15, or a fusion protein or diakine comprising at least two cytokines, wherein at least one of the at least two cytokines is IL-10 or IL-4, IL-12, IL-15 or IL-7, to reduce CRS associated with BiTE or CAR-T therapy. In one embodiment, monocytes are treated with IL-10, or IL-4, IL-12, IL-15, IL-7, or a half-life extended form thereof, or a diakine comprising at least one of at least two cytokines (IL-10 or IL-4, IL-12, IL-15 or IL-7). In another embodiment, the patient will be treated with IL-10 or its half-life extended form and BiTE or CAR-T. In another embodiment, the patient will be treated with IL-4 or its half-life extended form and BiTE or CAR-T. In another embodiment, the patient is treated with a diakine comprising any of IL-10 and IFN-α, IL-2, IL-4, IL-7, IL-12, IL-15, IL-21 or IL-27 in an amount sufficient to reduce CRS. In another embodiment, the patient is treated with a diakine comprising any of IL-4 and IFN-α, IL-2, IL-7, IL-10, IL-12, IL-15, IL-21 or IL-27 in an amount sufficient to reduce CRS.
[0007] On the other hand, the present application relates to a method of reducing BiTE or CAR-T-related CRS, comprising administering to a subject thereof a BiTE or CAR-T treatment mode in combination with IL-10, IL-4, or any combination thereof, or a diakine comprising at least one of IL-10, IL-4, and IL-2. In one embodiment, the method comprises administering a BiTE or CAR-T therapy to a patient in need thereof before, after, or simultaneously with the administration of IL-10 or IL-4, IL-12, IL-15, or IL-7, or a half-life extended form thereof, or a diakine comprising IL-10 or IL-4 in combination with IFN-α, IL-2, IL-7, IL-12, IL-15, IL-21, or IL-27.
[0008] In another aspect, the present application relates to a method of inhibiting the induction of proinflammatory cytokines in a patient receiving BiTE or CAR-T therapy, comprising administering to a patient receiving said therapy a dose of IL-10 or IL-4 or a half-life extended form thereof, or a diakine comprising IL-10 or IL-4 in combination with IFN-α, IL-2, IL-7, IL-12, IL-15, IL-21 or IL-27, in an amount sufficient to inhibit CRS caused by proinflammatory cytokines.
[0009] The brief overview of the above representative aspects is intended to provide a basic understanding of the present disclosure. This overview is not an extensive overview of all expected aspects, and is neither intended to identify the key or important elements of all aspects, nor to define the scope of any or all aspects of the present disclosure. Its sole purpose is to present one or more aspects in a simplified form as a preface to a more detailed description of the present disclosure that follows. To achieve the above objectives, one or more aspects of the present disclosure include the features described and exemplarily pointed out in the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 Figure 2 is a graph measuring the response of IL1β, IFNγ, TNFα, IFNα2a, IL-12, and IL-6 levels in PBMCs to increasing levels of IL-2 exposure.
[0011] Figure 2 Graph measuring IFNγ, IL-6 and TNFα levels induced by PBMCs in response to 1 ug / mL anti-CD3 in the presence of diakine, IL-10 and IL-2.
[0012] Figure 3 Serum cytokines of mice obtained by in vivo diakine exposure.
[0013] Figure 4 Nonhuman primate serum cytokine levels obtained for in vivo diakine exposure.
[0014] Figure 5 Figure 2 is a graph measuring the cytotoxicity of CD8+ T cells exposed to diakine and BiTE.
[0015] Figure 6 Figure 2 is a graph measuring IFNγ and TNFα levels in CD8+ T cells exposed to different concentrations of BiTEs.
[0016] Figure 7 Schematic diagram of the proposed IL-2-mediated CRS pathway in response to BiTE or CAR-T therapy.
[0017] Figure 8: Combination of an EGFR-targeted diakine containing IL-10 and IL-2 with a CD3xCD19 BiTE enhances CD8+ T cell-directed tumor cell lysis.
[0018] Fig. 9 :diakine(DK2 10 Combination of EGFR) with CD3xCD19 BiTE exhibits enhanced cytolytic effector molecules and controlled CRS
[0019] Fig.10 : Contains Raji GFP+ PBMC cultures of tumor cells were treated with diakine (DK2 10 FACS analysis of cells treated with EGFR and CD3xCD19BiTE DETAILED DESCRIPTION
[0020] Described herein are exemplary aspects of the method of suppressing (suppressing, inhibiting), alleviating or preventing CRS associated with BiTE or CAR-T treatment mode using IL-10, IL-4, IL-12, IL-15, IL-7 or its half-life extension form, or comprising at least one of IL-10 or IL-4 and IFN-α, IL-2, IL-7, IL-12, IL-15 or IL-27. It is described. One of ordinary skill in the art will appreciate that the following description is illustrative only and is not intended to be limited in any way. Other aspects will be easily thought of by those skilled in the art after benefiting from the present disclosure. The implementation of the exemplary aspects shown in the accompanying drawings will now be referred to in detail. Throughout the accompanying drawings and the following description, the same reference index will be used as much as possible to refer to the same or similar items.
[0021] Although a variety of methods and materials similar or equivalent to those described herein can be used in practice, the preferred materials and methods are described herein.
[0022] Unless otherwise indicated, the embodiments described herein use conventional methods and techniques of molecular biology, biochemistry, pharmacology, chemistry and immunology, which are well known to those skilled in the art.See, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Enzymology (Methods In Enzymology) (S.Colowick and N.Kaplan, Academic Press, Inc.); Handbook of Experimental Immunology, Volumes I-IV (DM Weir and CC Blackwell, Blackwell Scientific Publications); ALL Lehninger, Biochemistry (Biochemistry) (Worth Publishers, latest addition). Many general techniques for designing and manufacturing diakine have previously been described in U.S. Application Publication No. 20220017587. This includes types of IL-10 variants, including but not limited to human, mouse, CMV and / or EBV forms of IL-10, as well as assays for testing IL-10 variants, diakine and other known assay methods.
[0023] The following terminology will be used to describe the various embodiments discussed herein and is intended to be defined as described below.
[0024] As used herein when describing various embodiments, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise.
[0025] The term "about" refers to a deviation of 0.0001-5% from the indicated number or range of numbers. In one embodiment, the term "about" refers to a deviation of 1-10% from the indicated number or range of numbers. In one embodiment, the term "about" refers to a deviation of up to 25% from the indicated number or range of numbers. In a more specific embodiment, the term "about" refers to a difference of 1-25% in nucleotide sequence homology or amino acid sequence homology compared to the wild-type sequence.
[0026] The term "agent" is intended to be interpreted broadly when it comes to various interleukins (ILs) such as "IL-10 agents" or "IL-4 agents", and includes, for example, human and non-human forms of interleukin polypeptides, including homologs, variants (including mutant proteins), fragments thereof and fusion proteins, as well as polypeptides with, for example, leader sequences (e.g., signal peptides) and modified forms of the foregoing. The present disclosure also contemplates nucleic acid molecules encoding the foregoing substances, vectors containing nucleic acid molecules, and cells expressing interleukin agents (e.g., transformed cells and host cells). The terms "variant", "analogs" and "mutant proteins" refer to biologically active derivatives of reference molecules that retain the desired activity, for example, anti-inflammatory activity. Generally, the terms "variant", "analogs" and "mutant proteins" refer to one or more compounds having a natural polypeptide sequence and structure when it comes to polypeptides, with one or more amino acid additions, substitutions (whose properties may be conservative) and / or deletions relative to the natural molecule. For example, the terms "IL-10 variant", "variant IL-10", "IL-10 variant molecule" and their grammatical variants and plural forms are intended to refer to equivalent terms for variant forms of IL-10 amino acid (or nucleic acid) sequences that differ from wild-type IL-10 forms by 1-25% in sequence identity or homology. Thus, for example, an EBV IL-10 variant molecule is a molecule that differs from wild-type EBV IL-10 in that it has one or more amino acids (or nucleotide sequences encoding amino acids) added, substituted and / or deleted.
[0027] The term "fusion protein" refers to the combination or conjugation of two or more proteins or polypeptides to produce a new arrangement of proteins that does not normally exist in nature. A fusion protein is the result of covalently linking two or more proteins or polypeptides. The two or more proteins that make up the fusion protein can be arranged in any configuration from the amino terminus ("NH2") to the carboxyl terminus ("COOH").
[0028] The terms "homologs", "homology", "homologous" or "substantially homologous" refer to the percentage identity between at least two polynucleotide sequences or at least two polypeptide sequences. Sequences are homologous to each other when they exhibit at least about 50%, preferably at least about 75%, more preferably at least about 80%-85%, preferably at least about 90%, and most preferably at least about 95%-98% sequence identity over a defined length of the molecule.
[0029] The term "sequence identity" refers to the exact nucleotide-to-nucleotide or amino acid-to-amino acid correspondence. Sequence identity can range from 100% sequence identity to 50% sequence identity. Percent sequence identity can be determined using a variety of methods, including but not limited to directly comparing the sequence information between two molecules (a reference sequence and a sequence whose percent identity to the reference sequence is unknown) by aligning the sequences, calculating the number of exact matches between the two aligned sequences, dividing by the length of the reference sequence, and then multiplying the result by 100. Available computer programs can be used to help identify percent identity.
[0030] The terms "subject", "individual" or "patient" are used interchangeably herein to refer to a vertebrate, preferably a mammal. Mammals include, but are not limited to, mice, rodents, apes, humans, farm animals, sports animals, and certain pets.
[0031] The term "administering" includes routes of administration that allow the applied active ingredient to exert its intended function.
[0032] "Therapeutically effective amount" or "effective amount" when referring to, for example, the administration of an IL variant, fusion protein, dual cytokine fusion protein, or diakine thereof as described herein, refers to an amount sufficient to promote certain biological activities. These may include, for example, inhibition of myeloid cell function, enhancement of Kupffer cell activity, and / or CD8 + There was no effect or enhancement of CD8 T cells + T cell activity and blocking mast cell Fc receptor upregulation or preventing degranulation or promoting or enhancing the effect of combination therapy (e.g., CAR-T therapy) or inhibiting monocyte or macrophage induction of cytokines. Therefore, an "effective amount" will improve or prevent the symptoms or signs of a medical condition. An effective amount also means an amount sufficient to allow or promote diagnosis.
[0033] The terms "treat," "treating," or "treatment" refer to methods of alleviating the effects of a disease or condition. Treatment may also refer to methods of alleviating the underlying cause of the disease or condition itself, rather than just the symptoms. Treatment may be any reduction from natural levels, up to, but not limited to, complete elimination of the disease, condition, or symptoms of a disease or condition.
[0034] The term "half-life extension" as used in this application refers to a protein comprising one or more additional parts (e.g., proteins or pegylation) that prolongs and / or enhances the circulation time anywhere in the subject's body by 1-100 times longer than the protein in the absence of the additional parts. In a preferred embodiment, when referring to IL, the half-life extended IL refers to IL-10 or IL-4, IL-7, IL-12 or IL-15 conjugated to scFv, wherein the circulation time is 1-10 times longer than the IL in the absence of scFv. In other embodiments, the half-life extended form of IL will adopt the configuration of formula I NH2-(Y)-(X 1 )-(X 2 )-(Y)-COOH, in "Y" is any monomer of a homodimeric or heterodimeric cytokine; "X 1 ” is the VL or VH region obtained from the first monoclonal antibody; "X 2 " is a VH or VL region obtained from a first monoclonal antibody, When X 1 When VL, X 2 is VH, or when X 1 When VH, X 2 is VL, and wherein VH and VL together form a scFv.
[0035] The term "diakine" or "DK" as used in this application refers to a dual cytokine fusion protein comprising two monomers of a dimeric cytokine, which can be a homodimer such as IL-10 or an IL-10 variant, or a heterodimer such as IL-12 or an IL-12 variant, which is fused to a monomeric cytokine, such as IL-2, IL-4, IL-7, IL-15, IL-21, IL-28, IL-29, or fused to a dimeric cytokine, such as IL-12 or IL-10, wherein both the dimeric cytokine and the monomeric cytokine are fused to an antigen targeting domain that extends the half-life. Representative diakine are described in detail in U.S. Patent No. 11,292,822 (diakines based on IL-10) and co-pending U.S. Application No. 18 / 065,504 (diakines based on dual dimeric cytokines), both of which are incorporated herein by reference in their entirety. In one embodiment, a diakine that can be used in a method in combination with a BiTE or CAR-T is represented by Formula II NH2-(Y)-(X 1 )-(Z n )-(X 2)-(Y)-COOH(Formula II) in "Y" is any monomer of a homodimeric or heterodimeric cytokine; "X 1 ” is the VL or VH region obtained from the first monoclonal antibody; "X 2 " is a VH or VL region obtained from a first monoclonal antibody, When X 1 When VL, X 2 is VH, or when X 1 When VH, X 2 is VL and wherein VH and VL together form a scFv; "Z" is a second cytokine, wherein the second cytokine is any monomeric cytokine or another dimeric cytokine; and "n" is an integer between 0 and 2. In one embodiment, the dimeric cytokine may include IFN-α, IL-2, IL-4, IL-7, IL-10, IL-12, IL-15, IL-21, and IL-27. In other embodiments, the monomeric cytokine may include IL-6, IL-4, IL-1, IL-2, IL-3, IL-5, IL-7, IL-8, IL-9, IL-15, IL-21, IL-26, IL-27, IL-28, IL-29, GM-CSF, G-CSF, interferon-α, interferon-β, interferon-γ, TGF-β or tumor necrosis factor-α, tumor necrosis factor-β, basic FGF, EGF, PDGF, IL-4, IL-11, or IL-13. The VH and VL of diakine are scFvs, which can be derived from any monoclonal antibody, but are preferably derived from antibodies capable of targeting a specific antigen. The monoclonal antibody derived from scFv (applicable to Formula I and Formula II) is selected from EGFR; CD52; CD14; various immune checkpoint targets, such as but not limited to PD-L1, PD-1, TIM3, BTLA, LAG3 or CTLA4; CD19; CD20; CD22; CD47; GD-2; VEGFR1; VEGFR2; HER2; PDGFR; EpCAM; ICAM (ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5), VCAM, CD14, FAPα; 5T4; Trop2; EDB- FN; TGFβTrap; MAdCAM, β7 integrin subunit; α4β7 integrin; α4 integrin SR-A1; SR-A3; SR-A4; SR-A5; SR-A6; SR-B; dSR-C1; SR-D1; SR-E1; SR-F1; SR-F2; SR-G; SR-H1; SR-H2; SR-I1; SR-J1; CD123; CD33; BCMA; PSA; PSMA; CEA; GPC3; BCMA; DLL3; MUC17; CLDN18; gpA33; HIV or Ebola.In one embodiment, the scFv (applicable to Formula I and II) is an engrafted scFv in which the VH and VL framework regions are derived from a first antibody (e.g., an anti-Ebola antibody) and the CDRs are obtained from a second antibody (e.g., but not limited to EGFR; CD52; CD14; various immune checkpoint targets, such as but not limited to PD-L1, PD-1, TIM3, BTLA, LAG3 or CTLA4; CD19; CD20; CD22; CD47; GD-2; VEGFR1; VEGFR2; HER2; PDGFR; EpCAM; ICAM (ICAM-1, ICAM-2, ICAM-3, ICAM-4, IC AM-5), VCAM, CD14, FAPα; 5T4; Trop2; EDB-FN; TGFβ trap (TGFβTrap); MAdCAM, β7 integrin subunit; α4β7 integrin; α4 integrin SR-A1; SR-A3; SR-A4; SR-A5; SR-A6; SR-B; dSR-C1; SR-D1; SR-E1; SR-F1; SR-F2; SR-G; SR-H1; SR-H2; SR-I1; SR-J1; CD123; CD33; BCMA; PSA; PSMA; CEA; GPC3; BCMA; DLL3; MUC17; CLDN 18; gpA33; HIV or Ebola).In a preferred embodiment, the scFv is derived from an anti-Ebola antibody, wherein the VH and VL framework regions of the anti-Ebola antibody are replaced or implanted with 6 CDR regions from specific antibodies against: EGFR; CD52; CD14; various immune checkpoint targets, such as but not limited to PD-L1, PD-1, TIM3, BTLA, LAG3 or CTLA4; CD19; CD20; CD22; CD47; GD-2; VEGFR1; VEGFR2; HER2; PDGFR; EpCAM; ICAM (ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5), VCAM, CD14, FAPα; 5T4; Trop2; EDB-FN; TGFβ trap (TGFβTrap); MAdCAM, β7 integrin subunit; α4β7 integrin; α4 integrin SR-A1; SR-A3; SR-A4; SR-A5; SR-A6; SR-B; dSR-C1; SR-D1; SR-E1; SR-F1; SR-F2; SR-G; SR-H1; SR-H2; SR-I1; SR-J1; CD123; CD33; BCMA; PSA; PSMA; CEA; GPC3; BCMA; DLL3; MUC17; CLDN 18; gpA33; more preferably anti-EGFR, anti-MAdCAM, anti-VEGFR1, anti-VEGFR2, anti-PDGFR, or anti-CD14, anti-CD19, anti-CD20, or anti-CD22.
[0036] In another embodiment, the diakine that can be used in the method of combining with BiTE or CAR-T is a diakine described in U.S. Patent No. 11,292,822 (IL-10-based diakine) or co-pending U.S. Application No. 18 / 065,504 (bi-dimeric cytokine-based diakine), both of which are incorporated herein by reference in their entirety. In yet another embodiment, the diakine that can be used in the method of combining with BiTE or CAR-T is a protein represented by Formula III NH2-(IL-10)-(X 1 )-(Z n )-(X 2 )-(IL-10)-COOH (Formula III); in “IL-10” is a monomer; "X 1 ” is the VL or VH region from the first monoclonal antibody; "X 2 ” is the VH or VL region from the first monoclonal antibody; When X 1When VL, X 2 For VH or when X 1 When VH, X 2 for VL; wherein the first monoclonal antibody is an anti-Ebola antibody or a scFv framework region obtained therefrom; wherein the VL and VH of the anti-Ebola antibody include 3 light chain CDRs and 3 heavy chain CDRs, which are implanted with 3 light chain CDRs and 3 heavy chain CDRs from the second monoclonal antibody; “Z” is a cytokine other than IL-10; "n" is the integer 1; and Wherein the following variables in Table 1 are applicable to Formula III:
[0037] In additional embodiments, the diakine that can be used in the methods in combination with BiTEs or CAR-Ts is a diakine described in Tables 2a-2d and 3a-3d in co-pending U.S. application Ser. No. 18 / 065,504, which is incorporated herein by reference in its entirety.
[0038] In another aspect, the protein or nucleic acid molecule encoding the dual cytokine fusion protein or DK can be formulated into a pharmaceutical composition comprising a therapeutically effective amount of the dual cytokine fusion protein and a pharmaceutical carrier and / or a pharmaceutically acceptable excipient. The pharmaceutical composition can be formulated with commonly used buffers, excipients, preservatives, and stabilizers. The pharmaceutical composition comprising the dual cytokine fusion protein is mixed with a pharmaceutically acceptable carrier or excipient. Various pharmaceutical carriers are known in the art and can be used in pharmaceutical compositions. For example, the carrier can be any compatible, non-toxic substance suitable for delivering the dual cytokine fusion protein composition of the present application to a patient. Examples of suitable carriers include physiological saline, Ringer's solution, glucose solution, and Hank's solution. The carrier may also include any poloxamer commonly known to those skilled in the art, including but not limited to poloxamers of molecular weight 2900 (L64), 3400 (P65), 4200 (P84), 4600 (P85), 11,400 (F88), 4950 (P103), 5900 (P104), 6500 (P105), 14,600 (F108), 5750 (P123) and 12,600 (F127). The carrier may also include an emulsifier, including but not limited to polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, to name a few. Non-aqueous carriers such as fixed oils and ethyl oleate may also be used. Carriers may also include additives, such as substances that enhance isotonicity and chemical stability, such as buffers and preservatives, see, e.g., Remington's Pharmaceutical Sciences and US Pharmacopeia: National Formulary, Mack Publishing Company, Easton, Pa. (1984). Formulations of therapeutic and diagnostic agents may be prepared by mixing with physiologically acceptable carriers, excipients or stabilizers, for example in the form of lyophilized powders, slurries, aqueous solutions or suspensions.
[0039] The pharmaceutical composition is formulated for administration to the patient in a therapeutically effective amount sufficient to provide the desired therapeutic outcome. Preferably, this amount has minimal negative side effects. In one embodiment, the amount of the dual cytokine fusion protein administered will be sufficient to treat or prevent inflammatory diseases or conditions. In another embodiment, the amount of the dual cytokine fusion protein administered will be sufficient to treat or prevent immune diseases or conditions. In another embodiment, the amount of diakine or dual cytokine fusion protein administered will be sufficient to treat or prevent CRS mediated by BiTE or CAR-T therapy. The amount administered may vary from patient to patient and needs to be determined by considering the disease or condition of the subject or patient, the overall health of the patient, the method of administration, the severity of the side effects, etc.
[0040] The effective dose for a particular patient may vary according to a variety of factors such as the condition being treated, the patient's overall health, the method of administration, route and dosage, and the severity of side effects. The appropriate dose for a patient is typically determined by a clinician using parameters or factors known in the art that may affect treatment or be expected to affect treatment. Typically, the dose starts with an amount slightly below the optimal dose and is then increased in small increments until the desired or optimal effect is achieved relative to any negative side effects. Important diagnostic measures include those such as inflammatory symptoms or levels of inflammatory cytokines produced.
[0041] The method for determining the dosage of the currently described dual cytokine fusion protein is substantially similar to the method described in U.S. Patent No. 10,858,412. Typically, the dosage range of the currently described dual cytokine fusion protein is 0.01 mg / kg to 1 mg / kg, preferably 0.025 mg / kg to 0.5 mg / kg. The dual cytokine fusion protein can be administered daily, three times a week, twice a week, weekly, every two months, or monthly. An effective amount of the therapeutic agent will affect the level of CRS inhibition caused by BiTE or CAR-T therapy. In another embodiment, the dosage concentration of diakine is 0.1 ng / mL to 200 ng / mL, preferably 10 ng / mL to 100 ng / mL. Typically, the addition of diakine will reduce the dose required for the BiTE or CAR-T mode.
[0042] The composition of the present application can be orally administered or injected into the body. Oral formulations can also include compounds that further protect IL or DK molecules from gastrointestinal proteases. Injection is usually intramuscular injection, subcutaneous injection, intradermal injection or intravenous injection. Alternatively, intra-articular injection or other routes can be used in appropriate circumstances. The parenteral-administered dual cytokine fusion protein is preferably formulated into an injectable form (solution, suspension, emulsion) of a unit dose together with a pharmaceutical carrier and / or a pharmaceutically acceptable excipient. In other embodiments, the composition of the present application can be introduced into the patient's body through an implantable or injectable drug delivery system.
[0043] Those skilled in the art will recognize that adoptive cell therapy (e.g., adoptive T cell therapy) is well known and practiced according to previously described methods. See, e.g., U.S. Pat. No. 4,690,915. These methods may include autologous transfer (i.e., derived from the patient) or allogeneic transfer (i.e., derived from another subject other than the patient to be treated).
[0044] CAR-T or TCR-T cells are applied by known methods, and are routinely practiced by personnel familiar with adoptive cell therapy. In one embodiment, the method of application includes but is not limited to push injection, intravenous or subcutaneous injection, intraocular injection, periocular injection, subretinal injection, intravitreal injection, injection through the diaphragm, subscleral injection, intrachoroidal injection, intracameral injection, subocular injection, subconjunctival injection, sub-Tenon's injection, injection behind the eyeball, periocular injection or near sclera delivery after. In some embodiments, they are applied parenterally, intrapulmonary and intranasal or intralesional or intratumoral administration. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. In certain embodiments, recombinant engineering CAR-T or TCR-T is applied in a single push injection, multiple push injections or continuous infusion. Commonly known CAR-T therapies include idecabtagene vicleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, tisagenlecleucel or axicabtagene ciloleucel.
[0045] In one embodiment, the diakine and CAR-T are administered in separate, subsequent time periods, wherein, for example, the diakine (e.g., DK2) is administered prior to administration of the recombinant engineered CAR-T cells. 10 vegfr2 or dk2 10EGFR or any one mentioned in Table 1 above). In other embodiments, diakine and CAR-T are administered simultaneously. In other embodiments, diakine is administered 1-3 days before CAR-T therapy, then administered simultaneously with CAR-T, and / or administered 1-7 days after CAR-T administration. Diakine can be administered once a day or a week, or 2-3 times a week in combination or in combination with CAR-T. In another aspect, diakine is used in the amplification and / or thawing process of CAR-T cells before administration. After reconstructing CAR-T cells from cryopreserved stock, CAR-T is usually left to stand in the presence of CAR-T beneficial cytokines (e.g., low-dose IL-2). In one aspect, CAR-T cells can be primed or amplified from cryopreserved stock in the presence of diakine. In one aspect, CAR-T is amplified or stimulated in the presence of 0.001 to 300 ng / mL diakine, more preferably 0.01 to 200 ng / mL diakine.
[0046] Likewise, diakine and BiTE are administered in separate, subsequent time periods, wherein the diakine (e.g., DK2 10 CD20 or DK2 10 EGFR or DK2 10 HER2 or DK2 10 HER3) is administered 1-3 days before the administration of a BiTE (e.g., CD3xCD19 BiTE). In other embodiments, diakine is administered 1-3 days before the BiTE, then administered simultaneously with the BiTE, and / or administered 1-7 days after the BiTE is administered. Diakine can be administered once a day or a week, or combined or administered in conjunction with a BiTE 2-3 times a week. BiTEs generally follow the form of a bispecific antibody having anti-CD3 and anti-TAA fused together. In one embodiment, the method combines IL-10 or IL-4 or a half-life extended form thereof, or a diakine comprising IL-10 or IL-4 and IFN-α, IL-2, IL-7, IL-12, IL-15, IL-21 or IL-27 with a BiTE, such as a BiTE bispecific for CD3 and CD33, BCMA, CD19, CD20, CD22, PSMA, EGFR, DLL3, MUC17, CLDN18, CEA, HER2, HER3, EpCAM, gpA33, GPC3, GD25T4, VEGFR2, PDGFR, PDL1 or PD1, to name a few. In a preferred embodiment, the BiTE is anti-CD3 and anti-CD19, anti-CD20, anti-HER2, anti-HER3, anti-PSMA or anti-BCMA.
[0047] It is generally believed that CRS is associated with an accompanying increase in serum IL-6, IL-1β, TNFα, IFNα / γ, IL-12, and IL-23. Although these cytokines are generally associated with CRS, it is unclear whether one, two, or all of these cytokines work together to cause toxic side effects associated with CRS. The inventors believe that the potential root cause of CRS is the fact that many patients with severe CRS induced by BiTE or CAR-T treatment develop vascular leakage syndrome. Vascular or capillary leakage syndrome is also primarily regarded as a dose-limiting and usually fatal toxicity associated with high-dose IL-2 therapy. In addition, the inventors found that treating human peripheral blood mononuclear cells (PBMCs) or human whole blood cells with increased concentrations of IL-2 can lead to the induction of a group of proinflammatory cytokines similar to CRS. Figure 1 .
[0048] Without being bound by any particular theory, the inventors believe that the cytokine levels induced by treatment with IL-2 alone are comparable to those induced by treatment with a cytokine receptor antagonist containing IL-10 (e.g., DK2 10 Similarities between the apparent blockade of these secondary cytokines induced by diakine (EGFR) or IL-4, IL-12, IL-15, IL-7, or any combination thereof will inhibit or block IL-2 mediated CRS. Others have demonstrated that the addition of tumor cells expressing specific tumor associated antigens (TAA) to PBMCs with a titration range of anti-TAA:anti-CD3 BiTEs results in the induction of a range of proinflammatory cytokines. (Fu, 2019). BiTE stimulation appears to result in an initial induction of TNFα, IL-2, and IL-4, followed by other cytokines in temporal order. (Brandl, 2007). In the presence of diakine (DK2 10 In the absence of EGFR), IL-10, and IL-2, the levels of IFNγ, IL-6, and TNFα induced by PBMCs in response to exposure to anti-CD3 indicated that DK2 10 The presence of (EGFR) prevented the induction of significant secondary proinflammatory cytokines associated with CRS, which was distinct from increased IL-2 concentrations. Figure 2 In addition, IL-2 binds to high affinity EBV IL-10 (internally referred to as DV07, Seq ID No: 5) (referred to as DK2 10 Fusion of EGFR prevents PBMCs and anti-CD3 stimulated PBMCs from inducing IL-2-mediated secondary cytokines. Figure 2 Further investigation of the coupling of IL-10 and IL-2 indicated that DK2 10 (EGFR) application to mice prevented the induction of peripheral cytokines induced by IL-2 alone. Figure 3 In addition, with DK2 10 (EGFR) treatment of nonhuman primates also did not result in significant induction of peripheral plasma cytokines. Figure 4 .
[0049] In addition, pre-exposure of CD8+ T cells to diakine (e.g., DK2 10 (EGFR)) can significantly enhance the ability of cells to subsequently engage with BiTEs and achieve tumor cell lysis. Figure 5 Furthermore, these cells appeared to secrete similar levels of IFNγ but lower levels of TNFα compared with cells stimulated with BiTEs alone. Figure 6 Therefore, the inventors believe that the molecular circuit responsible for BiTE or CAR-T-mediated CRS is a cascade of proinflammatory cytokine release, which is first triggered by CD4+ T cell engagement with BiTE or CAR-T, subsequently triggering IL-2 secretion and inducing additional proinflammatory cytokine secretion by monocytes / macrophages. Figure 7 From monocytes / macrophages. Example 1: Diakine enhances BiTE-mediated tumor cell lysis
[0050] DK2 10 (EGFR) has been previously shown to prime CD8+ T cells in vitro and in vivo, subsequently leading to tumor cell lysis. See U.S. Pat. No. 11,292,822. Here, DK2 10 (EGFR) is a typical example of diakine, which has been shown to both enhance BiTE-mediated tumor cell lysis and inhibit BiTE-mediated CRS.
[0051] Initially, DK2 10 (EGFR) has been shown to enhance BiTE-mediated tumor cell cytotoxicity. In this in vitro model, DK2 was evaluated by multiple rounds of exposure of target tumor cells. 10 Combination anti-tumor effect of (EGFR) and CD19 BiTE.
[0052] CD8+ T cells were isolated from fresh donor Leukopaks by magnetic bead separation according to the manufacturer's recommended protocol (Miltenyi). The isolated CD8+ T cells were expressed at 2.5x10 6 Cells were seeded per well and exposed to different concentrations (0 or 100 ng / mL) of DK2 in AIMV. 10 (EGFR) for 2 days. 10(EGFR) After 2 days, CD8+ T cells were harvested, counted, washed, and finally resuspended in the corresponding concentration of DK2 10 (EGFR). At the same time, Raji cells constitutively expressing green fluorescent protein (GFP) were counted, washed, and resuspended in different concentrations (0 or 0.1 ng / mL) of CD19BiTE. CD8+ cells (effector cells) and Raji-GFP cells (target cells) were then combined at a 10:1 effector cell to target cell ratio. The S3 Live Cell Analysis System (Essen Bioscience / Sartorius) monitored the cells exposed to CD19 BiTE alone, DK2 alone, and 4% leukemia cells over a 5-day period. 10 (EGFR) or CD19BiTE and DK2 10 (EGFR) combined effector and target cell mixtures. In parallel, additional culture plates were seeded under the same conditions as above for subsequent and continuous cytotoxicity assays. The culture medium was aspirated from the wells every 3 days and fresh culture medium (with appropriate concentrations of DK2 10 (EGFR, CD19BiTE, or a combination of both) were added to the wells. After 5 days of exposure, cells were harvested, counted, washed, and re-exposed to similar conditions as described previously. The percentage of (GFP) disappearance was measured as an indicator of cytotoxicity.
[0053] CD3xCD19 BiTE in combination with DK2 10 (EGFR) can enhance cytotoxicity to tumor cells. Figure 5 and Figure 8 CD3XCD19 BiTE and DK2 were used to detect CD8+ T cells from normal, healthy human donors. 10 (EGFR) were tested individually and in combination. Figure 8 Effector cells were exposed to target tumor cells (Raji-GFP) for multiple rounds (5 rounds of serial cytolysis), and cytotoxicity was measured by the disappearance of GFP. 10 (EGFR) combination treatment showed that in the evaluation of CD8+ T cells against Raji GFP+ When answering, use DK2 10 (EGFR) activated T cells can enhance the response to BITE. Example 2: Diakine alleviates BiTE-mediated CRS
[0054] One of the current clinical challenges facing BiTE is the significant induction of CRS (Zhou, 2021). 10(EGFR)) treatment of peripheral blood-derived mononuclear cells (PBMCs), tumor-bearing mice, and nonhuman primates (see Figure 1 , 3 and 4) appear to prevent IL-2-mediated CRS, so in vitro cultures (including PBMC, Raji GFP+ Cells, with or without 100ng / mL DK2 10 0.1 ng / mL CD19 BiTE (EGFR) can be used to determine DK2 10 (EGFR) can inhibit BiTE-mediated CRS.
[0055] PBMCs were isolated from Leukopaks collected from healthy donors using the Ficoll density gradient method. Equal volumes of HBSS and donor samples were transferred to conical tubes. Ficoll was slowly added to form a bottom layer, and the samples were centrifuged at 400xg for 30 minutes at 25°C. PBMCs were harvested from the top layer and then washed twice with Aim V medium (300xg, 8 minutes). The isolated PBMCs were centrifuged at 2x10 6 Cells / well were seeded with different concentrations (0 or 100 ng / mL) of DK2 in AIMV. 10 EGFR and then incubated for two days (37°C, 5% CO2). Raji tumor cells were counted, washed, and resuspended in different concentrations of CD19 BiTE (final concentration of 0 or 0.1 ng / mL) with or without DK2 10 AIMVs of EGFR (100 ng / mL) were added and allowed to stimulate for two days. PBMCs (assumed to contain 10% CD8+ T cells (effector cells)) and Raji cells (target cells) were mixed at a 10:1 effector cell to target cell ratio. After 24 hours of incubation, supernatants were harvested and cytokine secretion was measured by multiple capture assay (MSD) and ELISA.
[0056] like Fig. 9 As shown, the data indicate that under these conditions, DK2 10 The presence of (EGFR) significantly promoted tumor cell lysis (induction of IFN-γ, granzyme B, and perforin) while limiting the induction of BiTE-mediated CRS at non-functional concentrations of BiTE (0.1 ng / mL). Representative data were collected 24 hours after exposure 1. Longitudinal data indicate that CRS is reduced over time under these conditions. Fig.10 .
[0057] To better understand PBMC+Raji GFP+ DK2 10We evaluated the cell types affected by EGFR by intracellular fluorescence-activated cell sorting (FACS) for 48 h in culture. This analysis showed that DK2 10 The presence of (EGFR) polarized CD4+ and CD8+ T cells to primarily express IFN-γ, while reducing the production of TNF-α and IL-2. MHC II-positive cells, called antigen presenting cells (APCs), also showed a reduction in the production of TNF-α, IL-6, and IL-1β, indicating that DK2 10 (EGFR) mediates pleiotropic cell type control of CRS associated with BiTE-mediated T cell activation. Fig.10 . References Bosco,MC(2000).Il-2 Signaling in Human Monocytes Involves thePhosphorylation and Activation of p59hck1.Journal of Immunology. Brandl,C.(2007).The effect of dexamethasone on polyclonal T cellactivation and redirected taget cell lysis as induced by a CD19 CD3bispecific single-chain antibody construct.Cancer ImmunologyImmunotherapy. Chen,Y.(2021).Therapeutic Potential of TNFa and IL-1b Blockade forCRS / ICANS in CART Therapy via Ameliorating Endothelial Activation.Frontiers in Immunology. Hosseini,I.(2020).Mitigating the risk of cytokine release syndrome inPhase I trial of CD20CD3bispecific antibody mosunetuzumab in NHL impact oftranslational system modeling.Systems Biology and Applications. Fu et al(1029).Therapeutic Bispecific T-Cell Engager AntibodyTargeting the Transferrin Receptor.Frontiers in Immunology. Liu,D.(2018).Cytokine release syndrome;grading,modeling,and newtherapy.Journal of Hematologyand Oncology. Maude,S.L.(2014).Managing Cytokine Release Syndrome Associated withNovel T Cell-Engaging Therapies.Cancer Journal. Musso,T.(1992).IL-2Induces IL-6Production in Human Monocytes.Journalof Immunology.Norelli,M.(2018).Monocyte-derived IL-1and IL-6aredifferentially required for cytokine release syndrome and neurotoxicity dueto CAR T cells.Nature Medicine. Shimabukuro-Vornhagen,A.(2018).Cytokine release syndrome.Journal ofImmunoTherapy of Cancer. Strieter,R.M.(1989).Interleukin-2-induced Tumor Necrosis Factor-alphaGene Expression in Human Alveolar Macrophages and Blood Monocytes.AmericanReview Respiratory Disease.
Claims
1. A method for reducing the severity of cytokine release syndrome (CRS) induced by a bispecific T cell engager (BiTE) or a chimeric antigen receptor T cell (CAR-T), the method comprising administering to a patient in need thereof an amount of a composition comprising interleukin 10 (IL-10) or an IL-10 agent, interleukin 4 (IL-4) or an IL-4 agent, or a combination thereof.
2. The method of claim 1, wherein the composition comprises human IL-10 or viral IL-10, muteins, variants, fusion proteins and fragments thereof.
3. The method according to claim 2, wherein the human IL-10 is the sequence of SEQ ID No:
1. 4 . The method according to claim 2 , wherein the viral IL-10 is Epstein Barr virus (EBV) IL-10 of SEQ ID No:
5.
5. The method of claim 1, wherein the IL-10 agent is a fusion protein comprising IL-10. The method of claim 1 , wherein the IL-4 agent is a fusion protein comprising IL-4.
7. The method of claim 6, wherein the fusion protein is a diakine comprising IL-10.
8. The method of claim 7, wherein the fusion protein is a diakine comprising IL-4.
9. The method of claim 7, wherein the diakine further comprises a scFv targeting domain that targets a receptor different from that of the BiTE or CAR-T.
10. The method of claim 8, wherein the diakine further comprises a scFv targeting domain that targets a receptor different from that of the BiTE or CAR-T.
11. The method of claim 10, wherein the scFv targets a receptor selected from the group consisting of EGFR, CD3, CD4, CD5, CD7, CD14, CD19, CD20, CD22, CD25, CD30, CD33, CD34, CD38, CD40, CD47, CD52, CD56, CD70, CD79B, CD117, CD123, CD138, CD147, BCMA, C-type lectin-like molecule-1 (CLL01), PD-L1, PD-1, TIM3, BTLA, latent membrane protein 1 (LMP-1), signaling lymphocyte activation molecule F7 (SLAMF7), NY-ESO-1, transmembrane activator and CAML interactor (TACI), CS-1, CXCR4, NKG2D, B7-H3, LAG3, CTLA4, GD-2, VEGFR1, VEGFR2, HER2, HER3, PDGFR, EpCAM, mesothelin (MSO), PSCA, PSA, MUC1, Lewis-Y, GPC3, AXL, Claudin 18.2, GD2, CEA, ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5, VCAM, FAPα, 5T4, Trop2, EDB-FN; TGFβ, Trap, MAdCAM, β7 integrin subunit, α4β7 integrin, α4 integrin, SR-A1, SR-A3, SR-A4, SR-A5, SR-A6, SR-B, dSR-C1, SR-D1, SR-E1, SR-F1, SR-F2, SR-G, SR-H1, SR-H2, SR-I1, SR-J1, HIV, or Ebola.
12. The method of claim 11, wherein the scFv targets a receptor selected from the group consisting of EGFR, CD3, CD4, CD5, CD7, CD14, CD19, CD20, CD22, CD25, CD30, CD33, CD34, CD38, CD40, CD47, CD52, CD56, CD70, CD79B, CD117, CD123, CD138, CD147, BCMA, C-type lectin-like molecule-1 (CLL01), PD-L1, PD-1, TIM3, BTLA, latent membrane protein 1 (LMP-1), signaling lymphocyte activation molecule F7 (SLAMF7), NY-ESO-1, transmembrane activator and CAML interactor (TACI), CS-1, CXCR4, NKG2D, B7-H3, LAG3, CTLA4, GD-2, VEGFR1, VEGFR2, HER2, HER3, PDGFR, EpCAM, mesothelin (MSO), PSCA, PSA, MUC1, Lewis-Y, GPC3, AXL, Claudin 18.2, GD2, CEA, ICAM-1, ICAM-2, ICAM-3, ICAM-4, ICAM-5, VCAM, FAPα, 5T4, Trop2, EDB-FN; TGFβ, Trap, MAdCAM, β7 integrin subunit, α4β7 integrin, α4 integrin, SR-A1, SR-A3, SR-A4, SR-A5, SR-A6, SR-B, dSR-C1, SR-D1, SR-E1, SR-F1, SR-F2, SR-G, SR-H1, SR-H2, SR-I1, SR-J1, HIV, or Ebola.
13. The method of claim 9, wherein the diakine comprising IL-10 further comprises a second cytokine selected from the group consisting of IFN-α, IL-2, IL-4, IL-7, IL-12, IL-15, IL-21, and IL-27.
14. The method of claim 10, wherein the diakine comprising IL-4 further comprises a second cytokine selected from the group consisting of IFN-α, IL-2, IL-7, IL-10, IL-12, IL-15, IL-21, and IL-27.
15. The method of claim 1, wherein the BiTE or CAR-T therapy targets a hematological tumor or a solid tumor selected from CD19, CD20 or CD22.
16. The method of claim 1, wherein the CAR-T target is selected from TNFRSF17, IL3RA, SDC1, CD5, CD19, CD20, CD22, CD23, CD33, CD38, CD44, CD70, CD133, CD174, CD274, CD276, CEACAM6, GFRA1, ITGB6, MS4A1, TNFRSF8, NCAM1, ULBP1, ULBP2, IL1RAP, CEACAM5, MET, EGFR, EGFRvIII, ENPP1, FGFR4, EPCAM, EPHA2, ERBB2, GPC3, MSLN, Muc1, PDCD1, KDR, IL13RA2, FOLH1, FAP, CA9, FOLR1, L1CAM, ROR1, SLAMF7, GD2, PSCA, GPNMB, CSPG4 or TEM1.
17. The method of claim 1, wherein the CAR-T therapy is idecabtagene vicleucel, lisocabtagene maraleucel, brexucabtagene autoleucel, tisagenlecleucel or axicabtagene ciloleucel.
18. A method for inhibiting cytokine release syndrome (CRS) in a patient receiving bispecific T cell engager (BiTE) or chimeric antigen receptor T cell (CAR-T) therapy, comprising administering a composition comprising interleukin 10 (IL-10) or an IL-10 agent to a patient in need thereof.
19. A method for inhibiting cytokine release syndrome (CRS) in a patient receiving bispecific T cell engager (BiTE) or chimeric antigen receptor T cell (CAR-T) therapy, comprising administering a composition comprising interleukin 4 (IL-4) or an IL-4 agent to a patient in need thereof.
20. A method of inhibiting the induction of proinflammatory cytokines in a patient receiving BiTE or CAR-T therapy, comprising administering a composition comprising interleukin 10 (IL-10) or an IL-10 agent or interleukin 4 (IL-4) or an IL-4 agent to the patient receiving the therapy.
Citation Information
Patent Citations
Antibody variable domain regions fused to IL-10 variant molecules
US10858412B2
Dual cytokine fusion proteins comprising IL-10
US11292822B2
Dual cytokine fusion proteins comprising il-10
US20220017587A1
Dual cytokine fusion proteins comprising multi-subunit cytokines
US20230287075A1
Adoptive immunotherapy as a treatment modality in humans
US4690915A
